Company intelligence
BIOCODEX
Healthcare with passion and conviction
About BIOCODEX
Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Women’s health; Orphan diseases. With more than 1,700 employees, Biocodex generated net revenues of above €500 million in 2023, including 1/3 in France and 2/3 internationally. The group is present in more than 100 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide. To report quality complaint(s) or adverse event(s) related to Biocodex products please visit https://www.biocoreport.com/en/
Verified activity
Signals from BIOCODEX
4 published signals
Presence & Recognition
BIOCODEX participated in the 16th European Epilepsy Congress in Athens.
Reported by BIOCODEX
Presence & Recognition
BIOCODEX participated in the 16th European Epilepsy Congress in Athens from September 5 to 9, 2026, as part of its commitment to Rare Diseases.
Reported by BIOCODEX
Presence & Recognition
BIOCODEX brand Saforelle is meeting travelers at Aéroport Marseille Provence with a dedicated kiosk in the Terminal 1 departure area from August 14 to October 31.
Reported by BIOCODEX
Research & Knowledge
BIOCODEX published a new Frontiers in Immunology publication in collaboration with Prof. Fernando Chirdo and his team at the Universidad Nacional de La Plata (Argentina) providing new insights into the mechanisms involved in intestinal protection.
Reported by BIOCODEX